Immunogenic Composition Targets Bacterial Recurrence in COPD

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are non-specific and do not effectively address the recurrence of bacterial infections, leading to frequent and recurrent exacerbations, which are costly and burdensome on healthcare systems.

Innovation Solution

An immunogenic composition comprising immunogenic polypeptides from Haemophilus influenzae or Moraxella catarrhalis, or fragments thereof, is used to treat or prevent the recurrence of AECOPD by identifying subjects with a history of bacterial exacerbations and administering the composition to induce a targeted immune response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If non-specific treatments are used for AECOPD, then the treatment approach is simple and easy to administer, but the frequency of recurrent exacerbations increases and treatment effectiveness decreases

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the treatment approach by identifying specific bacterial pathogens (H. influenzae, M. catarrhalis, S. pneumoniae) responsible for AECOPD exacerbations and developing targeted immunogenic compositions for each pathogen. This segmentation allows the treatment to address specific causes rather than using non-specific broad-spectrum approaches, thereby improving treatment effectiveness while maintaining manageable complexity through focused pathogen-targeting strategies.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent changes the treatment parameter from non-specific symptomatic management to specific pathogen-targeted immunization. By modifying the treatment approach to include immunogenic compositions that specifically target bacterial pathogens, the patent improves treatment effectiveness and reduces recurrence frequency, while the complexity increase is offset by the precision and针对性 of the approach.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If targeted immunogenic compositions are administered, then the frequency of AECOPD exacerbations is reduced, but the complexity of treatment increases

Engineering Contradiction:

Improvehealthcare efficiencyVSAvoidtreatment protocol complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent implements preliminary action by administering immunogenic compositions before AECOPD exacerbations occur. This preventive immunization approach targets specific bacterial pathogens in advance, priming the immune system to respond more effectively when exposure occurs. The result is reduced frequency and severity of exacerbations, improving healthcare efficiency by preventing rather than merely treating episodes, while the treatment protocol complexity is managed through standardized vaccination procedures.

Inventive Principle:

Principle #10Preliminary action

3Reliability

If broad-spectrum antibiotic therapy is used, then the initial exacerbation is treated, but recurrent bacterial infections occur frequently

Engineering Contradiction:

Improveinfection prevention efficacyVSAvoidtime between exacerbations

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent converts the harmful effect of recurrent bacterial infections into a benefit by using the known pathogen profiles from previous exacerbations to develop targeted immunogenic compositions. By identifying which specific bacteria (H. influenzae, M. catarrhalis, S. pneumoniae) caused prior exacerbations, the treatment leverages this information to create personalized preventive vaccines, transforming the pattern of recurrent infections into useful data for improving future prevention strategies and reducing time between exacerbations.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The immunogenic composition significantly reduces the frequency and severity of AECOPD exacerbations by targeting specific bacterial pathogens, thereby improving patient outcomes and reducing healthcare costs.

Implementation Method 1

An immunogenic composition comprising an immunogenic polypeptide from Haemophilus influenzae or an immunogenic fragment thereof and/or an immunogenic polypeptide from Moraxella catarrhalis or an immunogenic fragment thereof, for use in the treatment or prevention of a recurrence of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) associated with a bacterial infection in a subject

Methodology Applied

Scientific EffectImmunogenic response:

Data Source

PatentUS11167022B2Immunogenic composition, use and method of treatment

Publication Date: 2021.11.09 GLAXOSMITHKLINE BIOLOGICALS SA

AI summary

The present invention relates to immunogenic compositions comprising an immunogenic polypeptide from Haemophilus influenzae or an immunogenic fragment thereof and/or an immunogenic polypeptide from Moraxella catarrhalis or an immunogenic fragment thereof, for use in the treatment or prevention of a recurrence of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) resulting from a bacterial infection in a subject.